Navigation path

Pharmaceuticals - Community Register

  

Community list of not active orphan medicinal products


WITHDRAWN  

Product information

Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine)

EU orphan designation number: EU/3/12/1006
Active ingredient: Doxorubicin (administered after synthetic double-stranded siRNA oligonucleotide directed against claudin-5 complexed with polyethyleneimine)
Indication: Treatment of glioma
Sponsor: Avena Therapeutics Ltd
Trinity Research and Innovation, Trinity College Dublin, Dublin 2, Ireland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/11/2012 Orphan designation EMA/OD/019/12 (2012)8887 of 28/11/2012
11/04/2017 Removal of orphan designation from Community Register